Citation

87 FR 32031

Multiple canonical documents share this first-page citation.

Gilead Sciences, Inc.; Withdrawal of Approval of Indications for Relapsed Follicular Lymphoma and Relapsed Small Lymphocytic Lymphoma for ZYDELIG (Idelalisib) Tablets Thursday, May 26, 2022 87 FR 32031
National Center for Complementary & Integrative Health; Notice of Closed Meeting Thursday, May 26, 2022 87 FR 32031